Black Diamond Therapeutic Financials - Benzinga

Black Diamond Therapeutics Inc

BDTXNASDAQ

Trade with Public

Trade with Public

$2.19

0.136.31%

At close: Aug 19, 5:00 PM EST

$2.16

-0.03-1.37%

After Hours: 7:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Black Diamond Therapeutic Financials

Black Diamond Therapeutic (BDTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 10.53 percent increase over losses of $(0.19) per

Benzinga Newsdesk

PRO
CORRECTION: Black Diamond Therapeutic Q1 EPS $(0.16) Beats $(0.18) Estimate

Benzinga Newsdesk

PRO
Black Diamond Therapeutic Q4 EPS $(0.27) Misses $(0.19) Estimate

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.19) by 41.36 percent. This is a 3.57 percent increase over losses of $(0.28) per

Benzinga Newsdesk

US Stocks Mixed; Dollar Tree Posts Upbeat Earnings

Avi Kapoor

PRO
Black Diamond Therapeutic Q3 EPS $(0.15) Beats $(0.23) Estimate

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 35.9 percent. This is a 46.43 percent increase over losses of $(0.28) per

Benzinga Newsdesk

PRO
Black Diamond Therapeutic Q2 EPS $(0.19) Beats $(0.22) Estimate

Benzinga Newsdesk